Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

publishing date : 2021 - 09 - 02    tags : Treatment    save search

Sorrento Announces Enrollment of First Subject in Brazil Phase 2 Study of COVI-MSC for Treatment of COVID-19 Associated Acute Respiratory Distress in ICU Patients
Published: 2021-09-02 (Crawled : 16:00) - globenewswire.com
SRNE | $0.0275 -8.85% 53K twitter stocktwits trandingview |
Health Technology
| | O: 0.22% H: 1.42% C: -0.11%

covid treatment phase 2 brazil respiratory enroll
TCR² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of Cholangiocarcinoma
Published: 2021-09-02 (Crawled : 14:00) - globenewswire.com
TCRR 4 | $1.48 3.38% 3.9M twitter stocktwits trandingview |
Health Technology
| | O: 2.17% H: 1.28% C: -0.78%

treatment fda drug cel designation
Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment
Published: 2021-09-02 (Crawled : 14:00) - biospace.com/
RGC | $4.01 15.23% 13.22% 8.5K twitter stocktwits trandingview |
Manufacturing
| | O: 5.28% H: 9.58% C: -8.44%

covid treatment bioscience
Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19
Published: 2021-09-02 (Crawled : 12:00) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K twitter stocktwits trandingview |
Health Technology
| | O: 4.5% H: 0.86% C: -1.72%

covid treatment phase 2 phase 2/3 trial
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
Published: 2021-09-02 (Crawled : 07:00) - globenewswire.com
TLSA | $0.552 0.27% 0.27% 95K twitter stocktwits trandingview |
Health Technology
| | O: 12.12% H: 13.51% C: 8.11%
DTIL | $11.5 -10.65% -11.91% 220K twitter stocktwits trandingview |
Health Technology
| | O: 0.29% H: 4.58% C: 3.06%

treatment foralumab cancer antibody life science license car-t
Gainers vs Losers
56% 44%

Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M twitter stocktwits trandingview |
Health Technology

SINT | $0.0365 59.39% 37.26% 470M twitter stocktwits trandingview |
Health Technology

WISA 4 | $9.19 50.66% 33.7% 65M twitter stocktwits trandingview |
Electronic Technology

EDBL | News | $6.73 47.91% 32.39% 13M twitter stocktwits trandingview |

GCTK | $0.715 36.27% 26.62% 640K twitter stocktwits trandingview |
Manufacturing

TCON | $2.33 36.26% 26.61% 2M twitter stocktwits trandingview |
Health Technology

TIRX | $0.48 6.43% 24.58% 4.8M twitter stocktwits trandingview |

KZIA | $0.38 30.58% 23.42% 300K twitter stocktwits trandingview |
Health Technology

VNDA | News | $5.23 29.14% 22.56% 24M twitter stocktwits trandingview |
Health Technology

ATNF | $1.91 29.05% 22.51% 310K twitter stocktwits trandingview |


Your saved searches
Save your searches and get alerts when important news are released.